Business Context and Reporting Period
This Form 8-K was filed by Amedica Corporation (noted as Sintx Technologies in metadata) on March 6, 2018. The report details a material definitive agreement entered into on the same date regarding the amendment of previously issued Series E Common Stock Purchase Warrants.
Key Financial Metrics and Transaction Details
- Warrant Exercise: Investors exercised 600,000 warrants (out of 832,000 total) originally issued in July 2016.
- Price Reduction: The exercise price for the 600,000 exercised warrants was reduced from $12.00 to $2.125 per share.
- New Warrants Issued: The Company issued new warrants for 600,000 shares (100% of the exercised amount) at an exercise price of $2.00 per share.
- Remaining Warrants: 232,000 original Investor Warrants remain outstanding and exercisable at the investor's discretion.
- Placement Fees: A 6.0% fee on gross proceeds was paid to Maxim Partners, LLC, plus additional warrants covering 1.5% of the underlying shares.
Material Changes Versus Prior Period
The filing does not provide comparative financial data (revenue, profit, or cash flow) against a prior period. The material change reported is the restructuring of the Series E warrant terms, specifically the significant reduction in exercise price and the issuance of new warrants as consideration for the exercise of the original warrants.
Guidance, Outlook, and Risks
- Terms of New Warrants: The new warrants are exercisable for five years. They are subject to adjustment for stock splits, combinations, and dilutive issuances.
- Exercise Method: New warrants must be exercised for cash unless an effective registration statement is not available, in which case a cashless (net exercise) basis is permitted.
- Regulatory Status: The new warrants and underlying shares were issued in reliance on Section 4(2) and Rule 506 exemptions from registration. They cannot be offered or sold in the U.S. absent registration or an applicable exemption.
Investor Verification Checklist
- Verify the total gross proceeds received from the exercise of the 600,000 warrants at the reduced price of $2.125.
- Confirm the dilution impact of the 600,000 new warrants issued at $2.00 per share.
- Review the Company's current cash position to assess the impact of the 6.0% placement fee paid to Maxim Partners, LLC.
- Check the status of any registration statements covering the resale of shares underlying the new warrants to determine if cashless exercise is currently required.